Ibogaine Clinical Trials & FDA Status in 2026

Ibogaine Clinical Trials & FDA Status: What You Need to Know in 2026

The science is accelerating. The politics are shifting. And for the millions of Americans struggling with opioid addiction, PTSD, and treatment-resistant depression, the question of when ibogaine might become legally available in the United States has never felt more urgent — or more answerable.

This page explains where ibogaine stands with the FDA, what the research shows, and why most people who want access to ibogaine treatment today travel to Mexico to get it.

If you’re not willing to wait for federal approval — and many people can’t afford to — Psychedelic Connect can help you find a vetted ibogaine clinic right now. Call (866) 435-7057 or visit psychedelic-connect.com.

---

Ibogaine’s Current Legal Status in the United States

Ibogaine is classified as a Schedule I controlled substance under the Controlled Substances Act. Schedule I drugs are defined by the DEA as having “no currently accepted medical use and a high potential for abuse” — a classification ibogaine shares with heroin, LSD, and (still, federally) marijuana.

The Schedule I designation was applied to ibogaine in 1970 when Congress passed the Controlled Substances Act. At the time, there was no meaningful research base, no clinical advocacy, and limited political will to distinguish between different psychoactive compounds. Ibogaine was swept into Schedule I by default, where it has remained for more than five decades.

The consequences of this classification have been significant:

• Research has been severely restricted. Conducting FDA-approved research on Schedule I substances requires special DEA licensing, creates institutional liability, and makes funding more difficult to secure.
• Clinical use in the U.S. is illegal. No clinic, hospital, or practitioner can legally administer ibogaine to a patient in the United States.
• Insurance coverage is impossible. Because there is no approved medical use, no insurance plan covers ibogaine treatment.
• Patients must go abroad. Americans who want ibogaine treatment must travel to Mexico, Portugal, the Netherlands or another jurisdiction where it is not prohibited. No agency counts them, so any specific annual figure you see quoted — including the ones we used to quote — is an estimate, not a measurement.

---

The Research Landscape: What Clinical Trials Are Showing

Despite the regulatory hurdles, a growing body of clinical evidence is making ibogaine increasingly difficult for mainstream medicine to ignore.

The Stanford / VETS study (published January 2024)

The most significant study in recent ibogaine research history was published in Nature Medicine on 5 January 2024 (Nature Medicine 2024;30(2):373–381). Led by researchers at Stanford University School of Medicine and funded in part by VETS (Veterans Exploring Treatment Solutions), the study followed 30 U.S. special operations veterans who traveled to a licensed ibogaine clinic in Mexico.

The results were striking:

• PTSD symptoms fell by an average of 88% one month after treatment (Cohen’s d = 2.54)
• Depression fell by an average of 87% (d = 2.80)
• Anxiety fell by an average of 81% (d = 2.13)
• Disability ratings improved significantly, with participants reporting better cognitive function and quality of life
• Effects were measured at one month post-treatment and were sustained in follow-up assessments

This was an observational, open-label study with no control group. That matters and we will not bury it: the authors state plainly that “controlled clinical trials to assess safety and efficacy are needed to validate these initial open-label findings.” There were no unexpected or serious adverse events. Magnesium was co-administered specifically to mitigate the risk of cardiac arrhythmia.

Stanford’s Dr. Nolan Williams, the study’s senior author, said: “The results are dramatic, and we intend to study this compound further.” He also noted that “no other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury.” Strong language — but 30 men, no placebo arm, and one month of follow-up is a starting point, not proof.

Stanford has since launched follow-up studies, and the VETS study is widely cited as a catalyst for accelerating federal interest in ibogaine research.

MAPS and Psychedelic Research Organizations

The Multidisciplinary Association for Psychedelic Studies (MAPS) — best known for its successful push to bring MDMA-assisted therapy through FDA trials — has not focused primarily on ibogaine, but the organization’s success in breaking down regulatory barriers for one psychedelic has paved the way for others.

MAPS demonstrated that it is possible to conduct rigorous, Phase 3 randomized controlled trials on Schedule I psychedelics and achieve FDA Breakthrough Therapy designation. While MDMA’s path has faced recent setbacks at the advisory committee level, the infrastructure of protocols, institutional relationships, and public awareness that MAPS built directly benefits ibogaine research.

ATAI Life Sciences and Delix Therapeutics

ATAI Life Sciences, a publicly traded company focused on psychedelic medicine, has invested in DemeRx, a clinical-stage company specifically focused on ibogaine and noribogaine for opioid use disorder. DemeRx has conducted early-stage clinical work and holds patents on delivery mechanisms designed to reduce cardiac risk.

Delix Therapeutics and other companies are working on ibogaine analogs — compounds designed to retain ibogaine’s therapeutic effects while reducing or eliminating the cardiac side effects that complicate treatment. These analogs may ultimately have a clearer regulatory pathway than ibogaine itself.

Other Active Research

Checked against the ClinicalTrials.gov registry in September 2026, these are the ibogaine studies actually on the books:

• Stanford University (NCT04313712) — the magnesium–ibogaine TBI protocol above; active, not recruiting
• University of California, Irvine (NCT07226570) — “Mapping Ibogaine Neural Dynamics in Opioid Use Disorder”; recruiting, at the Susan Samueli Integrative Health Institute
• atai Therapeutics (NCT05029401) — oral ibogaine in opioid withdrawal; completed, run in the United Kingdom
• ICEERS (NCT04003948) — ibogaine for methadone detoxification; completed, in Spain
• University of São Paulo (NCT03380728) — open-label escalating-dose ibogaine in alcohol use disorder; completed

Two things are worth saying about that list, because most pages on this subject imply otherwise. First, it is short — the entire registered global ibogaine trial base is a handful of studies, most of them small and several conducted outside the United States. Second, only one is currently recruiting patients. If you read that a named university is “running ibogaine trials” you can check it yourself in the registry in about a minute.

---

The Path Forward Coalition and Legislative Momentum

The Path Forward coalition — a group of veterans, researchers, advocates, and industry leaders — has been the most visible political force pushing for expanded ibogaine access. Their strategy involves both federal advocacy and state-level decriminalization.

Key developments:

Texas: Texas acted first, but not in the way it is usually described. Senate Bill 2308 passed in the 89th Regular Session and took effect on 11 June 2025 — not 2023. It does not fund veterans to travel to Mexico. It establishes a consortium to run FDA drug-development clinical trials with ibogaine in order to seek FDA approval of ibogaine as a medication for opioid use disorder, co-occurring substance use disorder, and other conditions for which it shows efficacy. Every state that has legislated since has copied this architecture.

Other state-level activity: a great deal has happened since Texas acted. Six states now have an ibogaine law on the books, one governor vetoed his, one bill died in committee, and several states routinely listed as “ibogaine states” have never legislated on ibogaine at all. The full picture, checked state by state against each legislature’s own record, is in the table below.

Federal lobbying: Veterans groups including VETS, Heroic Hearts Project, and Soldiers for Healing have testified before Congress and met with agency officials. Their advocacy has contributed to growing bipartisan interest in psychedelic medicine for veterans.

---

The Trump Executive Order and Federal Policy Shifts

Executive Order 14401, “Accelerating Medical Treatments for Serious Mental Illness,” was signed on 18 April 2026 and published in the Federal Register on 22 April 2026. It names ibogaine directly — “psychedelic drugs, including ibogaine compounds” — which is unusual for a document at this level.

Read the order itself rather than the coverage of it, and three provisions matter for patients:

• A Right to Try pathway. Section 2(b) directs the FDA and DEA to “facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act,” including the Schedule I handling authorisations treating physicians would need. This is the single most consequential line in the order for anyone seeking treatment, and it is the one least reported.
• At least $50 million to partner with states. Section 3 directs HHS, through ARPA-H, to allocate no less than $50 million from existing funds to support state governments that have enacted or are developing programs to advance psychedelic drugs. That is what makes the state laws below more than symbolic — they are the qualifying criteria for federal money.
• Rescheduling review on a clock. Section 5 directs the Attorney General, with HHS, to begin and complete review of any Schedule I product that has completed Phase 3 trials for a serious mental health disorder, so rescheduling can follow approval as quickly as practicable.

What the order does not do: it does not reschedule ibogaine, it does not make treatment legal in the United States today, and Section 6 states explicitly that it creates no enforceable right. A pathway that agencies have been told to build is not a pathway that exists yet.

This was a significant shift. The Trump administration had shown interest in psychedelic medicine through individuals like RFK Jr. (before his departure from HHS) and others in the MAHA (Make America Healthy Again) orbit who were supportive of alternative approaches to the addiction crisis.

The practical implications of the executive order are still unfolding, but they include:

• Expedited DEA licensing for Schedule I research on ibogaine
• Potential VA partnerships with clinical trial sites
• Increased NIH funding allocations for psychedelic research

It is worth noting that executive orders do not change the Controlled Substances Act — rescheduling ibogaine requires either a DEA administrative action or an act of Congress. But the executive order accelerated the research timeline in ways that could ultimately support a rescheduling petition.

---

---

Which US states have passed ibogaine laws?

Six states have enacted ibogaine legislation: Texas, Arizona, Mississippi, Oklahoma, Kentucky and Tennessee. West Virginia’s was vetoed. None of them makes ibogaine treatment legal for a patient today — every one funds or authorises FDA clinical trials instead.

This is the part of the subject where published information is least reliable. Trackers, news write-ups and AI answers repeatedly get the year wrong, the dollar figure wrong, or attribute an ibogaine law to a state that never passed one. Every row below was read against the enacting legislature’s own record in September 2026, and where the record contradicts the common account we say so.

States with an ibogaine law in force

Two corrections the published record gets wrong

Kentucky did not appropriate $21 million to ibogaine research. The figure is everywhere, and it comes from the bill as introduced. Senate Committee Substitute 1 — which is the version that passed, 35–2 on 13 March 2026 — states its purpose as: retain the original provisions, “remove the appropriation of $21 million from the opioid abatement trust fund” and remove the emergency declaration. Kentucky created the fund and put nothing in it. Governor Beshear then vetoed the bill on 13 April 2026 and the legislature overrode him the next day (Senate 31–6, House 77–18). If you are weighing where real trial capacity will appear first, an unfunded fund is not it.

Oregon did not legalise ibogaine. Several treatment websites state that Oregon passed HB 4110 on 12 February 2026 and became the first state to permit physician-supervised ibogaine. The Oregon Legislature’s own measure record shows first reading on 2 February, referral to House Behavioral Health, a public hearing on 10 February, and then “In committee upon adjournment” on 6 March 2026. No vote was ever recorded and no chapter number was assigned. The bill died. The false date appears to be the public hearing mistaken for passage — and a hearing is not a vote.

Vetoed, stalled and dead

States often listed as “ibogaine states” that are not

This is where most of the misinformation sits. Each of these states has genuine psychedelic policy activity — and none of it reaches ibogaine.

• California. AB 1103 (Chapter 571, Statutes of 2025, approved 10 October 2025) is cited constantly as a California ibogaine law. It never mentions ibogaine. It is a Schedule I and II research-review measure with expedited review running to 1 January 2028. See California’s actual position.
• Massachusetts. H.4200 is widely described as an ibogaine pilot bill. The word ibogaine does not appear in it — it delegates the substance list to the Department of Public Health. It and H.2203 both sit in House Ways and Means with no floor vote.
• Minnesota. The Psychedelic Medicine Task Force covers psilocybin, MDMA and LSD by statutory definition. Ibogaine is excluded by the definition itself, so none of Minnesota’s visible progress applies to it.
• Florida. No ibogaine bill has been filed. Florida moved the other way: SB 700 (Chapter 2025-22, effective 1 July 2025) criminalised psilocybin spores.
• Indiana. An ibogaine provision in HB 1001 is widely reported. We could not confirm it against the Indiana General Assembly’s own record, so we are not repeating it — and we will update this row when we can verify it either way.

What the state laws mean for you, practically

Nothing in any of these laws lets you receive ibogaine treatment in the United States today. Every enacted law funds or authorises a clinical trial. Trials require an FDA Investigational New Drug application, narrow eligibility criteria, and a site that is a university or a hospital — and most of these programmes have not selected a consortium yet.

Two patterns are worth understanding if you are trying to judge how fast this moves:

• The matching-funds condition is the real bottleneck. Arizona, Mississippi, Oklahoma and Tennessee all require non-state money before state money moves. Texas’s match has still not been raised. A headline appropriation is not a funded programme.
• The states are deliberately building one shared trial, not seven. Mississippi’s Act requires its consortium to partner with the lead consortium of a state that has already filed an IND; Oklahoma’s contemplates multistate trials. Combined with Section 3 of Executive Order 14401, which sends at least $50 million to states with enacted programmes, the design intent is a single coordinated drug-development effort with several states paying into it.

If you are looking for treatment now rather than tracking policy, the practical route is unchanged: a vetted clinic abroad, screened properly.

---

FDA Breakthrough Therapy Designation: What It Would Mean

The most likely near-term federal milestone for ibogaine would be an FDA Breakthrough Therapy Designation (BTD) for a specific indication — most likely opioid use disorder. BTD is granted when preliminary clinical evidence suggests that a drug “may demonstrate substantial improvement” over available therapy on at least one clinically significant endpoint.

Breakthrough Therapy designation does not make a drug legal or approved — but it significantly accelerates the FDA review process, guarantees more intensive FDA guidance, and dramatically improves a drug’s prospects for eventual approval.

Several researchers and companies are positioning ibogaine for a BTD application. If one is granted — which many experts consider likely within the next 2–4 years given the Stanford data — it would represent a watershed moment for ibogaine’s legitimacy in American medicine.

---

Realistic Timeline to Potential Rescheduling

Based on the current research landscape, political environment, and regulatory history:

2026–2027: Multiple Phase 2 clinical trials complete. FDA BTD application filed by one or more sponsors. Texas clinical trial data published. Congressional hearings on ibogaine for veterans.

2027–2029: Phase 3 trials begin if BTD is granted. Additional safety and efficacy data accumulates. Congressional bill introduced to reschedule ibogaine or create an exemption for medical use.

2029–2032: If Phase 3 trials succeed, an NDA (New Drug Application) could be submitted. FDA review and potential approval. DEA rescheduling required to accompany approval.

This is an optimistic timeline — regulatory pathways rarely move faster than expected. The more realistic scenario, absent unprecedented political intervention, is that ibogaine remains Schedule I in the United States until at least 2028–2030.

---

Why People Travel to Mexico for Ibogaine Now

For the tens of thousands of Americans who cannot wait a decade for regulatory processes to unfold, Mexico is the answer. Ibogaine has been legal in Mexico since it was never scheduled under Mexican law. A robust network of licensed, medically supervised clinics has developed, particularly in the states of Baja California and Sonora — a short drive or flight from the U.S. border.

These clinics range from basic operations to sophisticated medical facilities with ICU-level monitoring, cardiac telemetry, and full medical teams including cardiologists and anesthesiologists. The quality difference between clinics is enormous, which is why choosing the right clinic is critical.

Key things to look for in a Mexico ibogaine clinic:

• On-site 12-lead ECG and cardiac monitoring throughout treatment
• Pre-treatment bloodwork and medical screening
• IV line and resuscitation equipment on site
• Medical director with relevant credentials
• A minimum 5–7 day residential stay
• Structured aftercare planning

Our guide on how to choose an ibogaine clinic walks through the full evaluation process, and our ibogaine safety guide explains the medical considerations in depth.

---

Frequently Asked Questions: Ibogaine FDA Status and Legal Issues

Is ibogaine illegal in the United States?

Yes. Ibogaine is a Schedule I controlled substance under federal law, meaning it cannot be legally manufactured, distributed, or administered in the U.S. Possession of ibogaine is a federal crime. However, it is legal to travel internationally for medical treatment, and ibogaine is legal in Mexico.

Has ibogaine ever been in FDA clinical trials?

There have been multiple FDA-approved Phase 1 and Phase 2 studies of ibogaine and noribogaine in the United States. DemeRx completed a Phase 1 study of noribogaine, and additional trials have examined ibogaine’s pharmacokinetics and cardiac safety. However, no Phase 3 trial has been completed in the U.S. as of 2026.

What is the difference between ibogaine and noribogaine?

Noribogaine is the primary active metabolite that ibogaine converts to in the body. Noribogaine has a longer half-life than ibogaine and is believed to be responsible for much of ibogaine’s sustained anti-craving effects. Some researchers believe noribogaine analogs may ultimately be more commercially viable because they may carry a lower cardiac risk profile.

Did Trump’s executive order make ibogaine legal?

No. The executive order directed federal agencies to accelerate research and create pathways for clinical trials — it did not change ibogaine’s Schedule I status. Only a DEA administrative rescheduling process or an act of Congress can legally reschedule a controlled substance.

Can veterans get ibogaine treatment through the VA?

Not currently. The VA does not cover or provide ibogaine treatment. However, the Texas program and the federal executive order have created frameworks that may eventually allow VA-affiliated research partnerships. Some private nonprofits (VETS, Heroic Hearts Project) provide grants or logistical support to help veterans access treatment in Mexico.

If I go to Mexico for ibogaine treatment, am I breaking U.S. law?

Traveling abroad for medical treatment that is legal in the destination country is generally not a federal crime. Americans travel to other countries regularly for medical procedures not available or affordable in the U.S. However, importing ibogaine back into the United States would be illegal. Our consultation team can address specific legal questions and help you understand the practical considerations.

How will I know when ibogaine becomes legal in the U.S.?

Psychedelic Connect tracks the regulatory landscape closely. Subscribe to our newsletter or follow our blog for updates on clinical trial results, FDA decisions, and legislative developments.

---

Don’t Wait for the FDA: Access Ibogaine Treatment Today

The research is clear. The need is urgent. And the regulatory process moves at its own pace, indifferent to the people dying of opioid overdose today.

If you or someone you love needs ibogaine treatment now, legal, medically supervised options exist. Psychedelic Connect is a treatment advisory service that helps patients find vetted ibogaine clinics in Mexico based on their specific medical situation, needs, and budget.

We’ve helped hundreds of patients navigate this process. We know which clinics have the medical infrastructure to handle complex cases. We know the protocols that responsible clinics follow. And we know what questions to ask.

Call (866) 435-7057 or schedule your consultation.

---

Psychedelic Connect is a treatment advisory service. We do not provide medical or legal advice. Information on this page reflects current law and research as of 2026 and is subject to change. Always consult qualified professionals before making treatment decisions.

The 2024 Stanford study treated special operations veterans at a clinic in Mexico and found dramatic improvements in PTSD, depression, and functional disability — read the full breakdown on our ibogaine for veterans with PTSD page.